OPEN END TURBO LONG - ASTRAZENECA | Market Closed - Börse Stuttgart 09:52:35 2024-05-31 EDT | ||
| 5.52 EUR | +1.85% |
|
| 1 month | -1.43% | ||
| 3 months | +63.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 5.52 | +1.85% |
| 24-05-30 | 5.42 | +2.85% |
| 24-05-29 | 5.27 | -5.22% |
| 24-05-28 | 5.56 | -3.47% |
| 24-05-24 | 5.76 | -2.04% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 09:52 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MC8CP6 |
| ISIN | DE000MC8CP64 |
| Date issued | 2020-04-07 |
| Strike | 7,430 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.04 € |
|---|---|
| Lowest since issue | 0.064 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
